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Research
Malignant pleural mesothelioma (MPM) is a
rapidly fatal malignancy with a median survival
time of < 1 year. The single most important
risk factor for MPM is exposure to asbestos,
which occurs in ≥ 70–80% of these patients
(Robinson and Lake 2005; Tammilehto et al.
1992). More than 3,000 deaths can be attrib-
uted to MPM each year in the United States,
and worldwide its incidence is on the rise
(Morinaga et al. 2001; Pelin et al. 1994; Price
1997; Price and Ware 2004; Roushdy-
Hammady et al. 2001). As a result of the pro-
found disease risk associated with exposure to
asbestos and the occupational setting where
exposure often occurs, litigation related to
asbestos disease—estimated at $265 billion over
the next 40 years—has become a tremendous
economic burden (Bhagavatula et al. 2001).
Although MPM incidence trends may plateau
and begin to decline in the coming years in the
United States (Price 1997; Price and Ware
2004), asbestos-containing products are still
imported into the country. Moreover, asbestos
use in other nations remains widespread and
signiﬁcant (Robinson and Lake 2005). 
Following diagnosis of MPM, the options
for treatment are in part dictated by known
prognostic factors. Notable predictors of
reduced survival in this disease are male sex
and nonepithelioid histologies (Zellos and
Christiani 2004). Recently, Flores et al.
(2007) reported that a history of asbestos
exposure is associated with reduced survival.
In an effort to conﬁrm and extend this obser-
vation, we used both self-reported (n = 128)
and quantitative asbestos burden measures
(n = 80) in a subset of cases to examine the
relationship between asbestos exposure and
MPM treatment outcome. 
Materials and Methods 
Study population and exposure data. Lung tis-
sue and tumor tissue were obtained following
surgical resection of pleural mesothelioma
from incident cases seen at the International
Mesothelioma Program at Brigham and
Women’s Hospital during 2000–2006. All
patients provided written informed consent
under the approval of the appropriate institu-
tional review boards. 
Clinical information was obtained from
review of each patients’ medical record.
Pathologic diagnosis and date of diagnosis were
obtained from the medical record of the initial
diagnosis, either at Brigham and Women’s
Hospital or the primary referring clinic, after
having been confirmed by a pathologist’s
review (J.G.G.). Each patient (n = 128) was
assessed for history of exposure to asbestos by a
trained industrial hygienist (83 cases had avail-
able asbestos body burden data), and additional
demographic and environmental data on medi-
cal and occupational history was obtained
through an in-person questionnaire or inter-
view. Patients were followed up for survival
using the National Death Index (National
Center for Health Statistics 2007) to determine
date of death. Surviving patients were censored
(n = 48) based on their last known clinic visit. 
We quantified asbestos bodies (ABs) in
samples of lung tissue from multiple sites
in the resected lung (De Vuyst et al. 1998);
ABs per gram of lung (wet weight) were cal-
culated as previously described (Churg and
Warnock 1977). 
Statistical analysis. We performed uni-
variate tests for association between asbestos
exposure, asbestos body burden, patient
demographic, and tumor characteristic data
using SAS software (SAS Institute Inc., Cary,
NC). Similarly, tests for association between
these variables and survival were carried out
with log-rank tests on Kaplan-Meier survival
probability plot strata. Also, we used a Cox
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BACKGROUND: Malignant pleural mesothelioma (MPM) is a rapidly fatal asbestos-associated malig-
nancy with a median survival time of < 1 year following diagnosis. Treatment strategy is determined
in part using known prognostic factors. 
OBJECTIVE: The aim of this study was to examine the relationship between asbestos exposure and
survival outcome in MPM in an effort to advance the understanding of the contribution of asbestos
exposure to MPM prognosis.
METHODS: We studied incident cases of MPM patients enrolled through the International
Mesothelioma Program at Brigham and Women’s Hospital in Boston, Massachusetts, using survival
follow-up, self-reported asbestos exposure (n = 128), and a subset of cases (n = 80) with quantitative
asbestos ﬁber burden measures.
RESULTS: Consistent with the established literature, we found independent, signiﬁcant associations
between male sex and reduced survival (p < 0.04), as well as between nonepithelioid tumor histology
and reduced survival (p < 0.02). Although self-reported exposure to asbestos was not predictive of
survival among our cases, stratifying quantitative asbestos ﬁber burden [number of asbestos bodies
per gram of lung (wet weight)] into groups of low (0–99 asbestos bodies), moderate (100–1,099),
and high ﬁber burden (> 1,099), suggested a survival duration association among these groups (p =
0.06). After adjusting for covariates in a Cox model, we found that patients with a low asbestos bur-
den had a 3-fold elevated risk of death compared to patients with a moderate ﬁber burden [95% con-
ﬁdence interval (CI), 0.95–9.5; p = 0.06], and patients with a high asbestos burden had a 4.8-fold
elevated risk of death (95% CI, 1.5–15.0; p < 0.01) versus those with moderate exposure.
CONCLUSION: Our data suggest that patient survival is associated with asbestos fiber burden in
MPM and is perhaps modiﬁed by susceptibility. 
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covariates when examining overall patient
survival. 
Results
We obtained tumor and lung tissue from
patients during surgical resection, and although
surgically treated patients tend to be slightly
younger and have more epithelioid disease
compared to the total MPM patient popula-
tion, this cohort is highly similar to other surgi-
cally treated cohorts (Pass et al. 2008). Survival
data were available on all 128 cases; of these,
83 cases had available asbestos body burden
data. Among the cases with available AB
counts, three had extremely high counts—
14,870, 19,681, and 303,852 ABs per gram of
wet weight lung (ABs/g lung)—compared to
the median count of 158. To avoid an analysis
anchored by extreme values, we did not include
data from these three patients.
In Table 1, we present exposure, demo-
graphic, and tumor histology data for all
128 cases and for the subset of 80 cases with
asbestos burden data. Cases with asbestos bur-
den data did not differ significantly from
cases without ﬁber burden data.
“Survival time” was defined as the time
from diagnosis to death or last known follow-
up. Figure 1 shows the Kaplan-Meier survival
probability plots stratified by sex, and the
log-rank test indicates a signiﬁcantly reduced
survival for males compared to females
(p < 0.04). Similarly, Figure 2 shows the
Kaplan-Meier survival plots by tumor histol-
ogy. These data reveal a signiﬁcant difference
in survival between patients with epithelioid
and nonepithelioid histologies (log-rank
p < 0.02), as well as a significant difference
among epithelioid, biphasic, and sarcomatoid
histologies (log-rank p < 0.01). 
We then examined the relationships
among asbestos exposure, asbestos fiber bur-
den, patient demographics, tumor histology,
and survival data, and we found a signiﬁcant
difference among asbestos ﬁber burden levels
and survival. Among all 128 cases, self-
reported exposure to asbestos was not predic-
tive of survival in MPM (log-rank p = 0.44;
data not shown). However, we observed a sig-
nificant association between self-reported
asbestos exposure and older age at diagnosis
(reported exposure, 62.0 ± 9.5 years; no
reported exposure, 56.9 ± 9.7 years; t-test,
p < 0.05), as well as between male sex and
reported asbestos exposure (Fisher’s, p <
0.0001; data not shown). Quantitative
asbestos burden data from 80 cases showed
that males (median count, 219 ABs/g lung;
range, 0–6,211) had significantly higher
asbestos burden than females (median count,
20 ABs/g lung; range, 0–2,437; Wilcoxon
p < 0.0001). Models of survival by asbestos
exposure did not demonstrate a linear trend;
thus, data were stratiﬁed into tertiles for sub-
sequent analysis. After stratifying asbestos
burden data into tertiles of low burden
(0–99 ABs/g lung), moderate burden
(100–1,099 ABs/g lung), and high burden
(> 1,099 ABs/g lung), we found an associa-
tion of fiber burden with survival among
these groups that approached statistical signif-
icance (Figure 3; log-rank p = 0.06). Using a
Cox proportional hazards model to adjust for
covariates, cases with low asbestos fiber bur-
den had a 3-fold elevated risk of death [95%
conﬁdence interval (CI), 0.95–9.5; p = 0.06]
compared to cases with moderate burden
(Table 2). Patients with high asbestos fiber
burden had 4.8-fold elevated risk of death
(95% CI, 1.5–15.0; p < 0.01) compared to
patients with moderate burden (Table 2).
Including the three cases with extreme outly-
ing asbestos counts in this model did not sig-
niﬁcantly alter the results (data not shown).
Discussion
In this study we evaluated the relationships
among asbestos exposure, asbestos ﬁber burden,
patient demographics, tumor histology, and
survival in MPM. Similar to other groups, we
found that male sex and nonepithelioid histolo-
gies predict reduced survival (Flores et al.
2007). Interestingly, we also demonstrated that
after correcting for covariates, low or high lung
tissue asbestos burden predicted a higher risk of
death compared to moderate asbestos burden. 
Historically, most asbestos exposure is
occupationally related and affects individuals
who mined, manufactured, or applied
asbestos-containing products (McDonald and
McDonald 1980). Given that men are more
Christensen et al.
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Table 1. Demographics and tumor characteristics of mesothelioma patients.
Total Asbestos burden data
Characteristic (n = 128) (n = 80)
Sex
Female 30 (23) 20 (25)
Male 98 (77) 60 (75)
Age (years)
Range 30–85 30–80
Mean ± SD 62 ± 10.1 61 ± 9.8
Histology
Epithelioid 91 (71) 60 (75)
Mixed 33 (26) 18 (22.5)
Sarcomatoid 4 (3) 2 (2.5)
Asbestos exposurea
Yes 95 (74) 59 (74)
No 33 (26) 21 (26)
AB count (ABs/g lung)b
Range (median) NA 0–6,211 (128)
Mean ± SD NA 875 ± 1,467
NA, not applicable. Values are number (%) except where indicated.
aSelf-reported. bData for 83 cases available; three outliers removed.
Figure 1. Kaplan-Meier survival probability plots of MPM patients (n = 128) by sex, using the log-rank
method to test for a difference between strata. Males (n = 98) had signiﬁcantly reduced survival compared
to females (n = 30; p < 0.04). Surviving patients (n = 48) were censored.
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Censoredlikely to be employed in asbestos-associated
occupations, it is not surprising that they have
higher levels of ﬁber burden and that the ratio
of men to women with MPM is between 3:1
and 5:1 (Zellos and Christiani 2004). Our
case series follows this pattern: Men with
MPM have a significantly higher lung tissue
asbestos burden and outnumber women more
than three to one. Men have both higher ﬁber
burdens and significantly reduced survival
compared to women, making it reasonable to
posit that an increased asbestos fiber burden
may contribute to poor survival per se.
Consistent with this, we observed an increased
risk of death among patients with high asbestos
burden compared to patients with moderate
asbestos burden. However, we also found an
increased risk of death among patients with the
lowest lung tissue asbestos burden versus those
with moderate ﬁber burden. 
The mechanism responsible for this
unusual dose–response association with sur-
vival is unclear. One possibility is that cases
with low asbestos burden were exposed to
chrysotile asbestos or other naturally occurring
mineral ﬁbers, such as erionite, that have been
associated with MPM (Carbone et al. 2002).
Chrysotile asbestos is less biopersistent and is
considered by many to be less pathogenic than
amphibole asbestos. Hence, signiﬁcant expo-
sure to chrysotile could have occurred in those
with lower numbers of ABs, and this might
not be evident in our data. However, lung
chrysotile ﬁber burden has been shown to cor-
relate with asbestos body levels, arguing
against signiﬁcant chrysotile exposure (Butnor
et al. 2003). 
Concomitantly, erionite ﬁbers are reported
to have the highest carcinogenic potential of
studied fibers, and form ferruginous bodies
indistinguishable from ABs (Dumortier et al.
2001). Because erionite fibers do not form
ferruginous bodies as readily as asbestos ﬁbers,
the AB counts in individuals with erionite
exposure may underestimate their true internal
dose (Dumortier et al. 2001). The worldwide
geographic distribution of erionite is very lim-
ited; therefore, it is unlikely that patients in this
study had this exposure. However, if either of
these scenarios were true (patients with low AB
counts having signiﬁcant chrysotile or erionite
exposure), it would imply that the ﬁber dose is
directly associated with survival. 
Asbestos and survival in mesothelioma
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Table 2. Asbestos body burden predicts survival in MPM, Cox’s proportional hazards model. 
Covariate No. (%) Hazard ratio (95% CI) p-Value
Sex 
Male 60 (75) 1.0 (reference)
Female 20 (25) 0.72 (0.27–1.9) 0.94
Histology
Epithelioid 54 (77) 1.0 (reference)
Mixed 14 (20) 0.82 (0.38–1.8) 0.62
Sarcomatoid 2 (3) 3.7 (0.35–39.1) 0.28
AB count (ABs/g lung)
0–99  37 (46) 3.0 (0.95–9.5) 0.06
100–1,099  21 (26) 1.0 (reference)
> 1,099 22 (28) 4.8 (1.5–15.0) <0.01
The model controlled for age and all variables shown.
Figure 2. Kaplan-Meier survival probability plots of MPM patients (n = 128) based on tumor histology, using the log-rank method to test for a difference between
strata. (A) Survival of patients with an epithelioid tumor (n = 91) and those with a mixed or sarcomatoid tumor (n = 37); patients with a nonepithelioid tumor had sig-
niﬁcantly reduced survival compared to those with an epithelioid tumor (p < 0.02; n = 128). (B) Survival of patients with an epithelioid (n = 91), biphasic (n = 33), or
sarcomatoid tumor (n = 4); survival was signiﬁcantly different among patients with the three tumor types (p < 0.01). Surviving patients (n = 48) were censored.
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Figure 3. Kaplan-Meier survival probability plots of MPM patients based on asbestos burden, using the log-
rank method to test for a difference among strata. Survival differences among exposure groups approaches
statistical signiﬁcance (p = 0.06). Eighty patients had AB counts; surviving patients (n = 48) were censored.
1.0
0.8
0.6
0.4
0.2
0.0
S
u
r
v
i
v
a
l
 
f
r
a
c
t
i
o
n
0 1 02 03 04 05 06 0
Time (months)
0–99 ABs/g lung (n = 37)
100–1,099 ABs/g lung (n = 21)
> 1,099 ABs/g lung (n = 22)
CensoredChristensen et al.
726 VOLUME 116 | NUMBER 6 | June 2008 • Environmental Health Perspectives
A more likely explanation of our results is
related to the considerable literature that has
documented both the absence of an apprecia-
ble threshold for asbestos-induced meso-
thelioma, and the fact that MPM can occur
with very low-level exposures (Hansen et al.
1998; Hodgson and Darnton 2000). Further,
widespread exposures to asbestos, particularly
environmental exposures in some parts of the
world, combined with the rare incidence of
mesothelioma, suggest that there may be sus-
ceptible individuals. In fact, multiple reports
indicate that genetics may modify susceptibility
to MPM (Ascoli et al. 1998; Dawson et al.
1992; Dogan et al. 2006; Hammar et al. 1989;
Li et al. 1978; Lynch et al. 1985; Martensson
et al. 1984; Otte et al. 1990; Precerutti et al.
1990; Risberg et al. 1980). When closely
examining our asbestos ﬁber burden data, we
found that most of the cases within the low-
asbestos-burden group (0–99 ABs/g lung) had
AB counts within the general population mean
of 0–20 ABs/g lung (Dodson and Atkinson
2006); thus these patients may have a greater
inherent susceptibility. Further, our data lead
to the hypothesis that patients with high sus-
ceptibility suffer from more aggressive disease.
Outside this high susceptibility group, the
other two tertiles demonstrated a dose–
response relationship between asbestos fiber
burden and survival. 
In summary, our data suggest that patient
survival is associated with asbestos ﬁber bur-
den in pleural mesothelioma and that this
association is perhaps modiﬁed by susceptibil-
ity. Studies using larger case groups—ideally
with chrysotile and erionite exposure data—
are necessary to further elucidate the ability of
asbestos burden to predict survival in MPM.
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